European Biotechs Lead Next-Gen Cell & Gene Therapy Manufacturing Innovation: From Scalable Stem Cells to Clinical CAR Treg Trials

June 28, 2026

PharmTech ヨーロッパ

Overview

European biotech companies are pioneering next-generation manufacturing technologies crucial for the commercial viability and accessibility of cell and gene therapies (CGTs), prioritizing scalable allogeneic production and cost reduction. Key advancements include TreeFrog Therapeutics’ C-Stem technology for massive stem cell expansion, Oxford Biomedica’s enhanced lentiviral vector production, and Touchlight Genetics’ enzymatic synthetic DNA. Further pushing clinical boundaries, Quell Therapeutics has advanced its autologous CAR Treg therapy into Phase 1/2 clinical trials, aiming to revolutionize immune-modulatory treatments.

In Depth

Background

The cell and gene therapy (CGT) sector holds immense promise for transforming disease treatment but grapples with significant manufacturing complexities, high costs, and scalability challenges. Autologous therapies, which require individualized manufacturing for each patient, are particularly expensive and logistically intensive. Overcoming these hurdles hinges on the development of allogeneic, “off-the-shelf” therapies. European companies are at the forefront of driving advancements in process streamlining, cost reduction, and enhancing therapeutic accessibility, thereby fueling the growth of this critical field.

Key Findings

European biotech companies are at the vanguard of developing innovative manufacturing technologies crucial for the commercial viability and broad accessibility of cell and gene therapies (CGTs). TreeFrog Therapeutics, leveraging its proprietary C-Stem technology, is demonstrating the potential for massive, standardized stem cell expansion, which could dramatically lower manufacturing costs for future cell therapies. Concurrently, Quell Therapeutics has advanced its autologous CAR Treg therapy into Phase 1/2 clinical trials, signaling significant progress in delivering advanced immune-modulatory treatments to patients with autoimmune diseases and organ transplant rejection.

Technical Developments

TreeFrog Therapeutics’ C-Stem Technology: This platform enables efficient, large-scale cultivation of stem cells within 3D hydrogel capsules, yielding homogeneous cell populations. This method significantly improves scalability and consistency compared to traditional 2D culture systems, promising substantial cost reductions and enhanced reliability in cell therapy manufacturing.
Oxford Biomedica’s Lentiviral Vector Manufacturing: The company is actively enhancing its capacity and efficiency in producing lentiviral vectors, which are vital components for gene therapies like CAR-T. A recent commercial supply agreement with Bristol Myers Squibb underscores its robust technical expertise and high-volume production capabilities.
Touchlight Genetics’ Enzymatic Synthetic DNA: Enzymatic DNA synthesis offers a faster and more flexible alternative to traditional plasmid-based methods for gene therapy vector production. This innovation has the potential to significantly shorten development timelines and simplify the manufacturing process.
Quell Therapeutics’ CAR Treg Clinical Trials: Their autologous CAR Treg cell therapy, precisely engineered to treat autoimmune diseases and prevent organ transplant rejection, has successfully entered Phase 1/2 trials. This clinical progression follows promising preclinical data and represents a strategic move towards validating this novel immune-modulatory therapeutic modality in humans.

Strategic Significance & Outlook

These technological breakthroughs are poised to significantly improve the commercial feasibility of cell and gene therapies, ultimately facilitating broader patient access globally. Platform technologies such as TreeFrog Therapeutics’ C-Stem are critical enablers for the mass production of allogeneic iPSC-derived therapies, directly addressing current manufacturing bottlenecks. A successful outcome for Quell Therapeutics’ CAR Treg therapy could revolutionize existing treatment paradigms for a wide range of autoimmune and inflammatory diseases. Europe’s proactive leadership in these manufacturing innovations is expected to generate a positive ripple effect across the entire global CGT ecosystem, accelerating the delivery of life-changing therapies.

Source: https://www.pharmtech.com/view/european-biotechs-developing-next-generation-cell-and-gene-therapy-manufacturing-technologies

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.